Company: IMNN
Filing Date: 2025-06-09
Form Type: 8-K
Source: 0001641172-25-014279
Chunk: 0

Company: Imunon, Inc.
Filing Date: 2025-06-09
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01. Other Events.

As
previously disclosed, on November 26, 2024, Imunon, Inc. (“the Company”) received a letter from the staff (the “ Staff”)
of The Nasdaq Stock Market LLC (“ Nasdaq”) indicating that, based upon the closing bid price of the Company’s common
stock, for the previous 30 consecutive business days, the Company was not in compliance with the requirement to maintain a minimum bid
price of $1.00 per share (the “ Minimum Bid Price Requirement”) for continued listing on The Nasdaq Capital Market, as set
forth in Nasdaq Listing Rule 5550(a)(2) (the “ Original Notice”). In order to regain compliance with the rule, the Company
is required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days. As of the close of market
on June 6, 2025, the closing bid price of the Company’s common stock was above $1.00 per share for the prior 10 consecutive business
days.

As
previously reported, the Company received a delisting determination letter on May 28, 2025 (the “ Delisting Determination Letter”)
in connection with the Minimum Bid Price Requirement, as well as a deficiency letter received by the Company on May 19, 2025 from the
Staff notifying the Company that it is no longer in compliance with the minimum stockholders’ equity requirement (the “ Minimum
Stockholders’ Equity Requirement”) for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(b)(1).
The Delisting Determination Letter stated that unless the Company requested a hearing before a Nasdaq Hearing Panel (“ Panel”)
to appeal Nasdaq’s delisting determination by June 4, 2025, trading of the common stock would have been suspended at the opening
of business on June 6, 2025, and the Company’s common stock would have been delisted from Nasdaq. On May 29, 2025, the Company
requested a hearing before the Panel, at which it will request a suspension of delisting pending its return to compliance. Pursuant to
Nasdaq Listing Rule 5815(a)(1)(B), the hearing request stayed the suspension of trading and delisting of the common stock pending the
conclusion of the hearing process. Consequently, the Company expects the common stock to remain listed on Nas